November 24, 2015
Kissei Pharmaceutical has entered into a license agreement with Swiss bioventure ObsEva SA for Kissei’s investigational endometriosis treatment KLH-2109 (development code), it said on November 20. Under the pact, Kissei will grant exclusive rights to develop and commercialize the agent...read more